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Background: Human natural killer (NK) cell activity is regulated by a family of killer cell 
immunoglobulin-like receptors (KIRs) that bind human leukocyte antigen (HLA) class I. 
Combinations of KIR and HLA genotypes are associated with disease, including sus-
ceptibility to viral infection and disorders of pregnancy. KIR2DL1 binds HLA-C alleles 
of group C2 (Lys80). KIR2DL2 and KIR2DL3 bind HLA-C alleles of group C1 (Asn80). 
However, this model cannot explain HLA-C allelic effects in disease or the impact of 
HLA-bound peptides. The goal of this study was to determine the extent to which the 
endogenous HLA-C peptide repertoire can influence the specific binding of inhibitory KIR 
to HLA-C allotypes.
results: The impact of HLA-C bound peptide on inhibitory KIR binding was investigated 
taking advantage of the fact that HLA-C*05:01 (HLA-C group 2, C2) and HLA-C*08:02 
(HLA-C group 1, C1) have identical sequences apart from the key KIR specificity deter-
mining epitope at residues 77 and 80. Endogenous peptides were eluted from HLA-
C*05:01 and used to test the peptide dependence of KIR2DL1 and KIR2DL2/3 binding 
to HLA-C*05:01 and HLA-C*08:02 and subsequent impact on NK cell function. Specific 
binding of KIR2DL1 to the C2 allotype occurred with the majority of peptides tested. In 
contrast, KIR2DL2/3 binding to the C1 allotype occurred with only a subset of peptides. 
Cross-reactive binding of KIR2DL2/3 with the C2 allotype was restricted to even fewer 
peptides. Unexpectedly, two peptides promoted binding of the C2 allotype-specific 
Abbreviations: CD3, cluster of differentiation 3; CHAPS, 3-[(3-cholamidopropyl) dimethyl ammonio]-1-propanesulfonate; 
CMV, cytomegalovirus; EBV, Epstein–Barr virus; EDTA, ethylenediaminetetraacetic acid; FACS, fluorescence-activated cell 
sorting; GFP, green fluorescent protein; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HLA, human leukocyte 
antigen; KIR, killer cell immunoglobulin-like receptor; MFI, mean fluorescence intensity; NK, natural killer; PBMC, peripheral 
blood mononuclear cell; PBS, phosphate-buffered saline; SP, single positive; TAP, transporter associated with antigen process-
ing; VSV, vesicular stomatitis virus.
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inTrODUcTiOn
Natural killer (NK) cells are innate lymphocytes with important 
roles in immune surveillance of cancer and viral infection (1). NK 
cell activation is regulated by an array of activating and inhibi-
tory receptors (2). Inhibitory receptors include CD94-NKG2A 
that binds human leukocyte antigen (HLA)-E and the killer cell 
immunoglobulin-like receptors (KIRs) that bind HLA-A, -B, and 
-C molecules (3). The specificity of inhibitory KIR for different 
HLA-C allotypes is defined by a dimorphism of a pair of amino 
acids at positions 77 and 80 of HLA-C, whereby KIR2DL1 binds 
group C2 allotypes (Asn77Lys80) and KIR2DL2 and KIR2DL3 bind 
group C1 allotypes (Ser77Asn80) (Figure 1A). Exchanging amino 
acids 77 and 80 from a C1 to a C2 allotype, and vice versa, revealed 
that position 80 was the key determinant of KIR specificity for 
C1 or C2 allotypes (4). A reciprocal dimorphism exists on the 
HLA-C-specific KIR at position 44, as KIR2DL2 and KIR2DL3 
(Lys44) can be converted into C2-binding receptors by mutation to 
Met44, the residue found in KIR2DL1, and vice versa (5). Genetic 
association studies have highlighted the importance of these 
interactions, linking combinations of KIR and HLA-C genes in 
the context of this C1–C2 model (Figure 1A), with multiple dis-
ease processes including susceptibility to infectious, autoimmune 
and inflammatory disease, cancer, and disorders of pregnancy (3, 
6–15). Examples include protection against chronic hepatitis C 
virus (HCV) infection in KIR2DL3 and HLA-C1 homozygotes 
and increased risk of pre-eclampsia and other pregnancy-related 
disorders when the fetus carries HLA-C2 (9–11).
KIR2DL3 with HLA-C1 is considered a weaker interaction 
than KIR2DL1 with HLA-C2, allowing disease associations to be 
explained through the “strength of inhibition” hypothesis, with 
weaker inhibitory receptor interactions leading to more NK cell 
activation and clearance of viral infections such as HCV (3, 6, 7, 
12–15). Understanding the basis for specificity in KIR binding 
to HLA-C allotypes is also relevant to hematopoietic stem cell 
transplantation for the treatment of certain leukemias, as the 
clinical outcome is improved when donor KIR and recipient 
HLA-C genes are mismatched according to the C1–C2 model for 
KIR specificity (16–18).
KIR2DL1 to the C1 allotype. We showed that presentation of endogenous peptides or 
HIV Gag peptides by HLA-C can promote KIR cross-reactive binding.
conclusion: KIR2DL2/3 binding to C1 is more peptide selective than that of KIR2DL1 
binding to C2, providing an explanation for KIR2DL3–C1 interactions appearing weaker 
than KIR2DL1–C2. In addition, cross-reactive binding of KIR is characterized by even 
higher peptide selectivity. We demonstrate a hierarchy of functional peptide selectivity 
of KIR–HLA-C interactions with relevance to NK cell biology and human disease asso-
ciations. This selective peptide sequence-driven binding of KIR provides a potential 
mechanism for pathogen as well as self-peptide to modulate NK cell activation through 
altering levels of inhibition.
Keywords: innate immunity, immunogenetics, natural killer cell, killer cell ig-like receptors, human leukocyte 
antigen
Killer cell Ig-like receptors interactions with HLA-C encom-
pass a role of bound peptide, in that certain peptide sequences 
are incompatible with KIR binding (19–21). The significance of 
HLA-C bound peptides in KIR binding for the control of NK cell 
immune responses has been highlighted by recent examples of 
HIV escape mutants that result in increased KIR binding due to 
single amino acid changes in particular viral epitopes (22, 23). 
The importance of side chains at positions 7 and 8 of 9 amino acid 
long peptides (9mers) was shown using amino acid-substituted 
peptide variants (19, 21, 24, 25). A study of 60 combinations of 
amino acid side chains at peptide positions 7 and 8 demonstrated 
that most combinations reduced KIR2DL2 and KIR2DL3 bind-
ing to HLA-C*01:02 (C1) compared to the parent peptide eluted 
from HLA-C (19). To date there is no established set of rules to 
determine the basis for peptide selectivity of KIR for binding 
HLA-C, although negatively charged residues at positions 7 and 
8 are poorly tolerated by KIR (19, 21).
Along with canonical binding to C1, KIR2DL2 and KIR2DL3 
display cross-reactive binding to C2 allotypes (26–28). In contrast, 
KIR2DL1 is highly specific for C2 allotypes, and no functional 
KIR2DL1 cross-reactivity with C1 allotypes has been reported 
(27–29). To determine the extent to which the endogenous HLA-C 
peptide repertoire can influence the specific binding of inhibitory 
KIR to HLA-C allotypes, naturally processed peptides were eluted 
from HLA-C*05:01 and sequenced. HLA-C*05:01, a classical C2 
allotype with a Lys at position 80, has shown particularly strong 
cross-reactivity with KIR2DL2 and KIR2DL3, despite lacking the 
group C1 Asn at position 80 (26, 27). Taking advantage of the 
fact that HLA-C*05:01 (HLA-C group 2, C2) and HLA-C*08:02 
(HLA-C group 1, C1) have identical sequences apart from the 
key KIR specificity determining epitope residues 77–80, we were 
able to use the same panel of peptides eluted from HLA-C*05:01 
to study the impact of HLA-C bound peptide on inhibitory KIR 
binding in the following interactions: canonical KIR2DL1–C2 
and KIR2DL2/3–C1 and cross-reactive KIR2DL2/3–C2 and 
KIR2DL1–C1.
We show that the majority of peptides tested facilitated the 
canonical KIR2DL1–HLA-C*05:01 (C2) interaction, whereas 
a more constrained set of peptides allowed the canonical 
AB
C
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FigUre 1 | continued
FigUre 1 | continued 
human leukocyte antigen (hla)-c*05:01 (group c2) and hla-c*08:02 
(group c1) are almost identical in sequence and hla-c*05:01-eluted 
endogenous peptides bind hla-c*05:01 and hla-c*08:02. (a) 
Schematic showing how the specificity of inhibitory KIR for different HLA-C 
allotypes is defined by an amino acid dimorphism at positions 77 and 80 of 
HLA-C, where KIR2DL1 binds group C2 allotypes (Asn77Lys80) and KIR2DL2 
and KIR2DL3 bind group C1 allotypes (Ser77Asn80). (B) Nucleotide sequence 
alignment of amino acid positions 77–80 of HLA-C*05:01 and HLA-C*08:02. 
Bold indicates nucleotide differences. (c) The motif for HLA-C*05:01 9mer 
peptides. (D) HLA-I expression on 221–C*05:01–ICP47 (left) and RMA-
S-C*08:02 (right) cells after overnight incubation at 26°C with 100 μM 
HLA-C*05:01 peptides P2, P10, and P11 and no peptide (NP). (e) HLA-I 
expression on 221–C*05:01–ICP47 (left) and RMA-S-C*08:02 (right) cells 
after overnight incubation at 26°C with 100 μM of 1 of 28 HLA-C*05:01 
peptides and NP. Mean MFI and SEM of three independent experiments are 
shown.
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KIR2DL2/3–HLA-C*08:02 (C1) interaction, indicating that the 
KIR2DL2/3–C1 interaction was more peptide selective than the 
KIR2DL1–C2 interaction. KIR2DL2 and KIR2DL3 cross-reactive 
binding to HLA-C*05:01 (C2) was even more peptide selective, 
while the KIR2DL1–HLA-C*08:02 (C1) interaction was highly 
peptide selective, occurring with just two peptides. Our results 
show that peptide sequence plays a significant role in KIR bind-
ing and NK cell function. This could be exploited by pathogens. 
It also suggests that a greater dependence on peptide sequence 
by KIR2DL2/3 may underlie functional differences between 
KIR2DL1 and KIR2DL2/3.
resUlTs
Kir2Dl2 and Kir2Dl3 Binding to 
hla-c*08:02 (c1) is More Peptide 
selective Than Kir2Dl1 Binding to 
hla-c*05:01 (c2)
To study the contribution of HLA-C bound peptides to KIR 
binding and specificity, we investigated the impact of KIR bind-
ing to HLA-C presenting identical peptides in the context of a 
C1 and a C2 allotype. HLA-C*05:01 (C2) is almost identical to 
HLA-C*08:02 (C1), differing only at the positions (77 and 80) 
that define the C1/C2 allotypes (Figure 1B; Additional File S1A 
in Supplementary Material). Peptides naturally bound to HLA-
C*05:01 were isolated from 721.221–C*05:01 (221–C*05:01) 
cells and analyzed by electrospray mass spectrometry. We 
identified 72 peptides of which 46 were 9mers with different 
relative abundance values (Additional File S2 in Supplementary 
Material). The motif for HLA-C*05:01 bound 9mer peptides 
showed an acidic residue at position 3 (Asp or Glu) and a 
predominantly hydrophobic anchor at position 9 (Figure 1C). 
The frequency of amino acids at each position in 9mers showed 
diversity of residues at most peptide positions, with positions 
3, 2, and 9 showing greater preference for particular amino 
acids (Figure  1C). All peptides contained an acidic residue 
(Asp or Glu) at position 3. Position 2 showed a preference 
for small residues (for example, Ala). The C-terminal anchor 
at position 9 was most commonly Leu, with Phe, Ile, Val, and 
TaBle 1 | Peptide sequence of 28 human leukocyte antigen-c*05:01 9mer peptides studied and their relative abundance at peptide elution.
Peptide sequence Protein of origin relative peptide abundance
P2 IIDKSGSTV AP-3 complex subunit mu-1 ++
P3 VGDKPVSNF Protein unc-119 homolog B +
P4 AVDGSGTKF Ribosome biogenesis protein WDR12 +
P6 IVDRGSTNL Alpha-adducin +
P7 YVDEHGTRL Proteasome subunit beta type-8 ++
P8 GSDPRVTQL RILP-like protein 2 ++++
P9 IVDRPVTLV NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 +++
P10 IVDKSGRTL Methionine synthase ++
P11 AGDDAPRAV β-Actin or POTE ankyrin domain family member F +++
P12 VSDQANHVL Kinesin-like protein KIF21A ++
P13 ASDHAPHTL CAD protein +
P14 VGDPHTVTV Bromodomain-containing protein 8 +
P15 KSDERPVHI E3 ubiquitin-protein ligase TRIM33 +
P16 ASDDGTVRI WD repeat-containing protein 26 ++
P17 SIDKTGENF 40S ribosomal protein S4, X isoform X isoform +
P18 TSDDVAKEF Protein unc-13 homolog C +++
P19 SADSKPIDV Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 +
P20 KLDETGNSL DNA topoisomerase 2-alpha ++
P21 MADRGEARL RecQ-mediated genome instability protein 2 ++
P22 AADFEIGHF Nucleosome assembly protein 1-like 1 +
P23 NADGKIISL Bifunctional glutamate/proline—tRNA ligase +++
P24 AADGKGVVV 60S ribosomal protein L28 ++
P25 AADKIHSSF Plasminogen activator inhibitor 2 ++++
P26 NADAIVVKL Staphylococcal nuclease domain-containing protein 1 +++
P27 NADTVSSKL AP-2 complex subunit beta +++
P28 SAEKAPVSV Transforming acidic coiled-coil-containing protein 1 +++
P29 QGDAVVLKI Immunoglobulin superfamily member 8 precursor +++
P30 AADHYSQQM Guanylate-binding protein 4 +
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Met also present. Our motif for peptides eluted and sequenced 
from HLA-C*05:01 was similar to a motif for HLA-C*05:01 
determined using combinatorial peptide libraries and binding 
data (30). As expected, a very similar peptide motif had been 
determined for HLA-C*08:02 (30).
A TAP-deficient HLA-C*05:01+ cell line was made by expres-
sion of the herpes simplex virus-derived TAP inhibitor ICP47 
(31) in 221–C*05:01 cells (221–C*05:01–ICP47; Additional File 
S1B in Supplementary Material). Of the 46 9mers identified by 
mass spectrometry, we synthesized the 28 9mer HLA-C*05:01 
peptides that included all combinations of amino acids found 
at positions 7 and 8 (Table 1). The peptide side chains at posi-
tions 7 and 8 have the greatest impact on KIR binding (19, 21, 
25, 32). Each of these peptides stabilized HLA-C expression 
on 221–C*05:01–ICP47 cells after overnight incubation at 
26°C, as well as HLA-C*08:02 expression on TAP-deficient 
RMA-S–C*08:02 cells (Figures  1D,E) (21). We used HLA-C-
transfected cell lines with two different mechanisms of TAP 
impairment (ICP47 or genetic TAP deficiency). There was a 
significant positive correlation between stabilization of HLA-C 
expression on both cell lines and a similar level of expression 
in the absence of peptide (Figures 1D,E; Additional File S1C 
in Supplementary Material). There were a few exceptions, for 
example, peptide 20. However, as most peptides stabilized 
HLA-C expression on both cell lines to similar extent, we 
conclude that amino acids 77 and 80 on the otherwise identical 
HLA-C*05:01 and HLA-C*08:02 do not have a strong influence 
on peptide loading of TAP-deficient cells. This provided us with 
the opportunity to compare the binding of KIR2DL1 to a C2 
allotype and KIR2DL2 and KIR2DL3 binding to a C1 allotype, 
using the identical peptide panel.
Soluble KIR-Ig fusion proteins (KIR-Fc) were used to examine 
KIR2DL1 binding to HLA-C*05:01 and KIR2DL2 and KIR2DL3 
binding to HLA-C*08:02 on peptide-loaded TAP-deficient cells 
(Figures  2A,B). Most peptides, 24 of 28, promoted binding of 
KIR2DL1-Fc to HLA-C*05:01 (C2) (Figure  2B). In contrast, 
KIR2DL2 and KIR2DL3 binding to HLA-C*08:02 (C1) occurred 
with only 13 and 11 of 28 peptides, respectively (Figure 2B). This 
finding remained the same when MFI results were normalized to 
HLA-I stabilization (KIF-Fc MFI/HLA-I MFI) by each peptide 
(Additional File S4 in Supplementary Material).
Thus, KIR2DL2 and KIR2DL3 showed greater selectivity for 
peptides than KIR2DL1 (13/28 and 11/28 compared to 24/28; 
p < 0.002, Chi-square test). Acidic side chains (Asp or Glu) at 
position 7 or 8 were present in three of the four peptides that 
did not promote KIR2DL1 binding, in line with previous stud-
ies (19, 21). These three peptides were also not able to promote 
KIR2DL2 and KIR2DL3 binding to HLA-C*08:02. Among the 
peptides that did not confer binding of KIR2DL2 and KIR2DL3, 
eight shared a positive charge at position 8 (Lys, Arg, or His), sug-
gesting these amino acids are poorly tolerated by KIR2DL2 and 
KIR2DL3. Among the 11 peptides that were good for KIR2DL2 
and KIR2DL3 binding, 7 had Ser or Thr at position 8 and the 
largest residue found at position 8 was Leu, suggesting a prefer-
ence for small amino acids. These data showed that KIR2DL2 
and KIR2DL3 are more stringent than KIR2DL1 in selection of 
peptide sequence for binding to HLA-C. The greater selectiv-
ity of KIR2DL2 and KIR2DL3 for peptide sequences seems to 
AB
FigUre 2 | Kir2Dl2 and Kir2Dl3 binding to human leukocyte 
antigen (hla)-c*08:02 is more peptide selective than Kir2Dl1 
binding to hla-c*05:01. (a) KIR2DL1-Fc binding to peptide-loaded 
221–C*05:01–ICP47 (left), KIR2DL2-Fc (middle) and KIR2DL3-Fc (right) 
binding to RMA-S-C*08:02 cells. Cells were loaded overnight at 26°C with no 
peptide (NP) or 100 μM HLA-C*05:01 peptides P2, P4, and P7. (B) Same as 
in panel (a). Killer cell Ig-like receptor (KIR-Fc) binding was assessed after 
overnight incubation at 26°C with NP or 100 μM of 28 individual 
HLA-C*05:01 peptides. Mean MFI and SEM of three independent 
experiments are shown. KIR-Fc (3.6 μg/ml) was conjugated to protein 
A-alexa 647.
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contradict their reported permissive, cross-reactive binding to 
group C2 HLA-C allotypes (26–28). The data suggest a funda-
mental difference between KIR binding to C1 and C2 allotypes. 
We next examined the contribution of peptide to KIR2DL2 and 
KIR2DL3 cross-reactive binding to HLA-C*05:01 (C2).
cross-reactive Kir2Dl2 and Kir2Dl3 
Binding to hla-c*05:01 (c2) is highly 
Peptide selective
Cross-reactivity of HLA-C*05:01 with KIR2DL2 and KIR2DL3 
(27) was confirmed, showing KIR2DL1-Fc, KIR2DL2-Fc, and 
KIR2DL3-Fc binding to 221–C*05:01 cells (Additional File 
S3A–C in Supplementary Material). The strength of binding 
followed the hierarchy KIR2DL1  >  KIR2DL2  >  KIR2DL3. 
The same hierarchy was observed with another C2 allotype, 
HLA-C*04:01 on 221–C*04:01 cells, as reported previously (26, 
27), despite weaker overall binding than that observed with 
221–C*05:01 cells (Additional File S3A–C in Supplementary 
Material). Additionally, an NK cell line expressing KIR2DL3 
(YTS–2DL3) was partially inhibited by 221–C*05:01 in cytotox-
icity assays, but not by 221–C*04:01 (Additional File S3D,E in 
Supplementary Material). Inhibition of KIR2DL3+ cells was also 
tested with primary NK cells, using a gating strategy described 
in a previous study (33). Single-positive (SP) KIR3DL1, SP 
KIR2DL1, and SP KIR2DL3 cells degranulated strongly in 
response to untransfected 221 cells (Additional File S3F–H in 
Supplementary Material). Expression of HLA-C*05:01 on 221 
cells had no impact on the degranulation of KIR3DL1-SP cells, 
while completely inhibiting the degranulation of KIR2DL1-SP 
NK cells and partially inhibiting KIR2DL3-SP NK cells 
(Additional File S3F–H in Supplementary Material). Thus, 
HLA-C*05:01 is a functional ligand for KIR2DL1, KIR2DL2, 
and KIR2DL3.
Next we tested whether KIR2DL2 and KIR2DL3 cross-
reactivity resulted from weaker binding across all peptides or 
greater peptide selectivity. In marked contrast to KIR2DL1-Fc 
binding to HLA-C*05:01 (Figure  2B), only five peptides con-
ferred cross-reactive binding to KIR2DL2-Fc and KIR2DL3-Fc 
(Figures  3A,B). Loading of peptides P2, P11, and P24, which 
have no amino acid in common at positions 7 and 8 (Table 1), 
resulted in the strongest binding. Thus, KIR2DL2 and KIR2DL3 
cross-reactive binding to HLA-C*05:01 was diminished, rela-
tive to that of canonical KIR2DL1, due to selective binding to a 
restricted subset of peptides.
Peptides that can promote cross-reactive KIR binding should 
occur by chance for every HLA-C allotype and can originate 
from endogenous host peptides as well as microbial pathogens. 
As an example, we tested five peptides derived from HIV Gag 
that stabilized HLA-I expression on 221–C*05:01–ICP47 cells. 
Two of them (Gag60–68 and Gag310–318) promoted canonical bind-
ing of KIR2DL1, and one (Gag310–318) promoted cross-reactive 
binding of KIR2DL2 and KIR2DL3 (Additional File S5A–E in 
Supplementary Material). These data provide a proof of principle 
that peptides of viral origin, similar to endogenously processed 
peptides, can promote cross-reactive KIR binding.
Peptide sequence Determines canonical 
and cross-reactive Kir2Dl2 and Kir2Dl3 
Binding
We then compared the contribution of peptide sequence to 
canonical and cross-reactive KIR2DL2 and KIR2DL3 binding 
to HLA-C*08:02 and HLA-C*05:01, respectively (Figure  4). 
Peptide 2 (P2; IIDKSGSTV) promoted strong KIR2DL2 
and KIR2DL3 binding to HLA-C*08:02 and HLA-C*05:01 
(Figure 2B; Additional File S4 in Supplementary Material). The 
role of peptide positions 7 and 8 in KIR binding to peptide 2 
(P2; IIDKSGSTV)-loaded HLA-C was explored using amino 
AB
FigUre 3 | cross-reactive Kir2Dl2 and Kir2Dl3 binding to the c2 
allotype human leukocyte antigen (hla)-c*05:01 is highly peptide 
selective. (a) KIR2DL2-Fc (left) and KIR2DL3-Fc (right) binding to 
peptide-loaded 221–C*05:01–ICP47, cells. Cells were loaded overnight at 
26°C with no peptide (NP) or 100 μM HLA-C*05:01 peptides P2, P10, and 
P11. (B) Same as in panel (a). Killer cell Ig-like receptors (KIR)-Fc binding 
was assessed after overnight incubation at 26°C with NP or 100 μM of 28 
individual HLA-C*05:01 peptides. Mean MFI and SEM of three independent 
experiments are shown. KIR-Fc (3.6 μg/ml) was conjugated to protein 
A-alexa 647.
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from an Ala substitution at position 8 than position 7. In con-
trast, these substitutions had no impact on canonical binding 
to HLA-C*08:02 (Figure 4A). The strong binding promoted by 
IIDKSGAAV was not due simply to the small side chain size, as 
substitutions with Gly (IIDKSGGGV) abolished cross-reactive 
binding to HLA-C*05:01 and substantially reduced canonical 
KIR2DL2 and KIR2DL3 binding to HLA-C*08:02 (Figure 4A). 
The impact of increased side chain size at position 8 was then 
tested by replacing position 8 in P2-AA (IIDKSGAAV) with Val 
(P2-AV; IIDKSGAVV) and Tyr (P2-AY; IIDKSGAYV). Val at 
position 8 had little impact on KIR2DL2 and KIR2DL3 binding, 
whereas Tyr at position 8 almost abrogated binding, suggesting 
that a bulky side chain impeded binding. Consistent with these 
results, a previous study showed that KIR2DL2 binding to HLA-
C*03:04 (C1) was sensitive to side chain size at position 8, with a 
preference for side chains no larger than Val (25).
In a previous study, KIR2DL2 binding to HLA-C*01:02 
was strongest with peptides having Leu or Phe at position 7 
(19). We tested KIR2DL2 and KIR2DL3 binding to P2-AA 
(IIDKSGAAV) substituted with Leu (P2-LA; IIDKSGLAV) or 
Phe (P2-FA; IIDKSGFAV) at position 7 and found that P2-LA 
(IIDKSGLAV) promoted the strongest binding of all peptides 
tested when presented on HLA-C*08:02 or HLA-C*05:01. In 
contrast, P2-FA (IIDKSGFAV) promoted weaker binding, a 
decrease which was more marked in cross-reactive KIR2DL2 
and KIR2DL3 binding to HLA-C*05:01, than in canonical bind-
ing to HLA-C*08:02.
The strong cross-reactive binding of KIR2DL2 and KIR2DL3 
to P11 (AGDDAPRAV, Figure 3) suggested a role for a positively 
charged residue at position 7 in binding. We tested this by sub-
stituting position 7 of P2-AA (IIDKSGAAV) with Lys (P2-KA; 
IIDKSGKAV) or Arg (P2-RA; IIDKSGRAV). While P2-RA 
(IIDKSGRAV) promoted strong KIR2DL2 and KIR2DL3 bind-
ing, P2-KA (IIDKSGKAV) was weaker, suggesting that a positive 
charge alone is not sufficient for strong binding (Figure  4A). 
Replacement of position 8 with Glu (P2-8E; IIDKSGSEV) or 
positions 7 and 8 with Glu (P2-EE; IIDKSGEEV) completely 
abrogated KIR2DL2 and KIR2DL3 binding to both HLA-C*08:02 
and HLA-C*05:01 (Figure 4A). This is consistent with our earlier 
results (Figure 2) and previous studies demonstrating that nega-
tively charged sides chains at position 7 or 8 are not competent 
for binding (19, 20), which is likely due to charge repulsion with 
the negatively charged KIR-binding face (24). In sharp contrast 
to KIR2DL2 and KIR2DL3 binding, canonical KIR2DL1 binding 
to HLA-C*05:01 was largely resistant to changes in amino acid 
sequence at position 7 or 8 except to those with acidic residues at 
position 7 or 8, similar to our results (Figure 2B) and previous 
studies (21).
contribution of Peptide sequence at 
Positions 7 and 8 to Kir Binding is 
Dependent on Peptide context
Canonical and cross-reactive KIR2DL2 and KIR2DL3 binding 
showed some similarities in preference for amino acids at posi-
tions 7 and 8. However, peptide 10 (P10; IVDKSGRTL) pro-
moted strong KIR2DL2 and KIR2DL3 binding to HLA-C*08:02, 
acid-substituted peptides, and binding was compared to that of 
canonical KIR2DL1 with HLA-C*05:01 (Figure 4). All peptides 
with amino acid substitutions at positions 7 and 8 had a similar 
capacity to stabilize HLA-C expression as the parent peptide 
(Additional File S6A–C in Supplementary Material). We first 
tested the impact of decreasing the size of amino acid side chains 
by substituting Ser at position 7 and Thr at position 8 of peptide 
2 with Ala, either singly (IIDKSGATV and IIDKSGSAV) or 
both (IIDKSGAAV). Each Ala-substituted peptide promoted 
enhanced and additive cross-reactive binding of KIR2DL2-Fc 
and KIR2DL3-Fc to HLA-C*05:01, with a greater contribution 
AB
FigUre 4 | canonical and cross-reactive Kir2Dl2 and Kir2Dl3 binding is controlled by amino acids at positions 7 and 8. (a) KIR2DL1-Fc, KIR2DL2-
Fc, and KIR2DL3-Fc binding to peptide-loaded 221–C*05:01–ICP47 (left, black) and KIR2DL2-Fc and KIR2DL3-Fc (right, gray) binding to RMA-S-C*08:02 cells. 
Cells were loaded overnight at 26°C with no peptide (NP) or 100 μM of peptide P2 (P2-IIDKSGSTV) and amino acid variants of peptide 2 with substitutions at 
positions 7 and 8. Amino acid sequence substitutions at positions 7 and 8 are shown. Mean MFI and SEM of three independent experiments are shown. Killer cell 
Ig-like receptors (KIR-Fc, 3.6 μg/ml) were conjugated to protein A-alexa 647. (B) KIR2DL1-Fc, KIR2DL2-Fc, and KIR2DL3-Fc binding to peptide-loaded 221–
C*05:01–ICP47 (left, black) and KIR2DL2-Fc and KIR2DL3-Fc (right, gray) binding to RMA-S-C*08:02 cells. Cells were loaded overnight at 26°C with NP or 100 μM 
of peptides P10 (P10-IVDKSGRTL), P11 (P11-AGDDAPRAV), and amino acid variants of P10 and P11 with substitutions at positions 7 and 8. Amino acid sequence 
at positions 7 and 8 is shown. Mean MFI and SEM of three independent experiments are shown. KIR-Fc (3.6 μg/ml) was conjugated to protein A-alexa 647.
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but weaker cross-reactive binding to HLA-C*05:01 (Figure 2B; 
Additional File S4 in Supplementary Material). In contrast, 
peptide 11 (P11; AGDDAPRAV) with similar side chains at 
positions 7 and 8 conferred canonical and cross-reactive bind-
ing. P10 and P11 share an Arg at position 7 and have small 
amino acids at position 8, both of which are compatible with 
canonical and cross-reactive binding (Figure 4B). These results 
suggest that factors other than side chains at positions 7 and 
8 impact on KIR2DL2 and KIR2DL3 binding. To examine 
this further, residues at positions 7 and 8 of P10 and P11 were 
substituted with Ala (P10-AA; IVDKSGAAL and P11-7A; 
AGDDAPAAV), a combination that promoted strong canoni-
cal and cross-reactive binding in the context of P2 (Figure 4A). 
These substitutions had opposite effects for P10 and P11 
(Figure  4B). P10-AA (IVDKSGAAL) was similar to P2-AA 
(IIDKSGAAV), promoting strong cross-reactive binding and 
maintaining strong canonical binding. In contrast, P11-7A 
(AGDDAPAAV) promoted almost no KIR2DL2 and KIR2DL3 
binding, be it canonical or cross-reactive (Figure 4B). In sum-
mary, Arg at position 7 is competent for KIR2DL2 and KIR2DL3 
cross-reactive binding in the context of P2 or P11, but not 
P10. Ala at positions 7 and 8 was competent for KlR2DL2 and 
KIR2DL3 binding in the context of P2 and P10, but not P11. 
Therefore, KIR2DL2 and KIR2DL3 binding to HLA-C*05:01 
and HLA-C*08:02 appears to be dependent on side chains at 
positions 7 and 8, but the contribution of specific amino acids 
at positions 7 and 8 is valid only in the context of a given 9mer. 
In contrast, KIR2DL1 binding to HLA-C*05:01 is strong in the 
presence of the majority of peptide variants accommodating 
various amino acid side chains, apart from those containing 
acidic residues (Figures 4A,B). Overall, the impact of amino 
acids at positions 7 and 8 on KIR2DL2 and KlR2DL3 binding 
was similar in the context of HLA-C*08:02 and HLA-C*05:01 
with a strong correlation in the presence of the same peptides 
(r = 0.8712, p < 0.0001; Additional File S6D in Supplementary 
Material). Cross-reactive binding of KIR2DL2 and KIR2DL3 
was more peptide selective than canonical binding.
Together, these data provide support for an argument that 
KIR2DL2 and KIR2DL3 canonical binding to HLA-C*08:02 is 
more peptide selective than that of KIR2DL1 to HLA-C*05:01, 
that cross-reactive binding to HLA-C*05:01 is even more peptide 
selective, and that binding is dependent on a combination of 
different side chains at positions 7 and 8 within a given peptide 
sequence context.
A B C
D E
FigUre 5 | high peptide selectivity, cross-reactive binding and functional inhibition of Kir2Dl3+ natural killer (nK) cells by hla-c*05:01 (c2). (a) 
Specific lysis of 221–C*05:01–ICP47 cells at different E:T by YTS-2DL3 NK cells. 221–C*05:01–ICP47 target cells were used after overnight culture at 26°C in the 
presence of no peptide (NP), P2, P2-AA, P2-EE, P2-GG, and P7. (B) Relative-specific lysis of 221–C*05:01–ICP47 cells by YTS-2DL3 NK cells compared to NP 
at10:1 (E:T). Mean and SEM of three independent experiments are shown. *** = p < 0.001 by Student’s t-test. (c) Flow cytometry histograms showing 
degranulation (CD107a expression) of KIR2DL3-SP (left) and KIR3DL1-SP (right) NK cells in response to 221–C*05:01–ICP47 cells loaded with P2, P2-AA, P2-EE, 
or NP. (D) Box plots showing the fraction of CD107a+ KIR2DL3-SP NK cells in response to 221–C*05:01–ICP47 cells loaded with P2, P2-AA, P2-EE, P2-GG, 
P2-LA, P11, P11-7A, P10, P10-AA, P10-7E, or NP (n = 3–5). The CD107a+ values were normalized to the fraction of CD107a+ KIR2DL3-SP NK cells that 
degranulated in the absence of peptide (set at 1.0) for each donor (CD107a+ ranged from 62.8 to 79.0%, n = 5). ***p < 0.001, **p < 0.01, and *p < 0.05 by 
Kruskal–Wallis test with Dunn’s multiple comparisons test. (e) KIR2DL3-Fc binding to 221–C*05:01–ICP47 cells correlated with degranulation (CD107a+) of 
KIR2DL3-SP NK cells in response to 221–C*05:01–ICP47 cells in the presence of P2, P2-AA, P2-EE, P2-GG, P2-LA, P11, P11-7A, P10, P10-AA, P10-7E, or NP. 
Spearman’s correlation r = −0.955, p < 0.0001. CD107a expression was normalized to value obtained in response to NP for each donor.
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high Peptide selectivity in Functional 
inhibition of Kir2Dl3+ nK cells by cross-
reactivity with hla-c*05:01 (c2)
We tested the capacity of KIR2DL2 and KIR2DL3 cross-reactive 
peptides to inhibit KIR2DL3+ NK cells when presented on HLA-
C*05:01. YTS cells expressing KIR2DL3 (YTS–2DL3) were tested 
for inhibition by 221–C*05:01–ICP47 cells that had been loaded 
with peptides. Inhibition of YTS–2DL3 cytotoxicity correlated 
well with the binding of KIR2DL3-Fc to HLA-C*05:01 (Figure 5). 
Strong inhibition was obtained with P2-AA (IIDKSGAAV), and 
partial inhibition with P2 (Figures 5A,B). Loading of peptides 
that did not promote KIR2DL3 binding to HLA-C*05:01 (P2-
GG, IIDKSGGGV; P2-EE, IIDKSGEEV; or P7, YVDEHGTRL) 
did not result in inhibition (Figures  5A,B). Inhibition of 
primary human NK cells was tested in degranulation assays. 
KIR2DL3-SP NK cells degranulated strongly in response to 
221–C*05:01–ICP47 cells that had not been loaded with peptide 
(Figures  5C,D). 221–C*05:01–ICP47 cells loaded with weaker 
binders such as peptides P2, P11, or P10 induced partial inhibi-
tion (Figures 4 and 5D), while those loaded with strong binders 
such as peptides P2-LA (IIDKSGLAV), P2-AA (IIDKSGAAV), 
or P10-AA (IVDKSGAAL) induced strong inhibition (Figures 4 
and 5D). While 221–C*05:01–ICP47 cells loaded peptides 
that did not promote binding such as P2-GG (IIDKSGGGV), 
P2-EE (IIDKSGEEV), P11-7A (AGDDAPAAV), and P10-7E 
(IVDKSGETL) induced as much degranulation as cells in the 
absence of peptide (Figures 4 and 5D). There was a strong inverse 
correlation between KIR2DL3-Fc binding to and degranulation 
of KIR2DL3-SP NK cells in response to 221–C*05:01–ICP47 cells 
loaded with the same peptides (Figure 5E).
As an internal control, degranulation of KIR3DL1-SP NK 
cells was not impacted by the presence of any of the peptides 
(Figure 5C; Additional File S7 in Supplementary Material). Thus, 
we have shown that the group C2 allotype, HLA-C*05:01 loaded 
with peptide that confers binding to KIR2DL3 induces functional 
inhibition of KIR2DL3+ NK cells.
Functional cross-reactive Kir2Dl1 
Binding to the c1 allotype, hla-c*08:02
KIR2DL1 is highly specific for the C2 allotypes (3). We put this 
specificity to the test by examining KIR2DL1 binding to HLA-
C*08:02 (C1) after loading with the same peptide panel that had 
been used to test canonical binding to HLA-C*05:01. We found 
two peptides that promoted KIR2DL1 binding to HLA-C*08:02 
(C1), peptides P10 (IVDKSGRTL) and P11 (AGDDAPRAV) 
(Figure  6A). For peptide P10, this KIR2DL1 cross-reactive 
binding was about twofold to threefold weaker than KIR2DL3 
binding to HLA-C*08:02 (Figures 2 and 6A). Peptides P10 (P10-
IVDKSGRTL) and P11 (P11-AGDDAPRAV) share an Arg at posi-
tion 7, and KIR2DL1 binding to HLA-C*08:02 was lost when Arg 
at position 7 of peptide P11 (P11-AGDDAPRAV) was replaced 
by Ala (P11-7A; AGDDAPAAV) (Figures 6A,B). To further test 
whether Arg at position 7 contributed to cross-reactive binding 
of KIR2DL1 to HLA-C*08:02, an Arg was substituted for the Ala 
A B C
D E
FigUre 6 | high peptide selectivity and functional cross-reactive binding of Kir2Dl1 to the c1 allotype human leukocyte antigen (hla)-c*08:02. (a) 
KIR2DL1-Fc binding to RMA-S-C*08:02 cells after overnight incubation at 26°C with no peptide (NP) or 100 μM of 28 individual HLA-C*05:01 peptides. Mean MFI 
and SEM of three independent experiments are shown. (B) KIR2DL1-Fc binding to RMA-S-C*08:02 cells after overnight incubation at 26°C with NP or 100 μM of 
peptides P10, P10-7E, P11, P11-7A, P2, P2-AA, P2-RA, P2-KA, and P2-EE. Mean MFI and SEM of three independent experiments are shown. KIR-Fc (3.6 μg/ml) 
was conjugated to protein A-alexa 647. (c) Flow cytometry histograms showing degranulation (CD107a expression) of KIR2DL1-SP (left) and KIR3DL1-SP (right) 
natural killer (NK) cells in response to 221–C*08:02–ICP47 cells pre-incubated overnight with P10, P10-7E, or NP. Expression of CD107a on KIR2DL1-SP NK cells 
with no target cells is also shown. (D) Box plots showing CD107a expression on KIR2DL1-SP NK cells in response to 221–C*08:02–ICP47 cells pre-incubated 
overnight with P10, P10-7E, P11, P11-7A, P2, P2-RA, P2-KA, P2-EE, or NP (n = 5–8). The CD107a+ values were normalized to the fraction of CD107a+ KIR2DL1-
SP NK cells that degranulated in the absence of peptide (set at 1.0) for each donor (CD107a+ ranged from 23.7 to 68.4%, n = 8). ****p < 0.0001 and **p < 0.01 by 
Kruskal–Wallis test with Dunn’s multiple comparisons test. (e) KIR2DL1-Fc binding to RMA-S-C*08:02 cells is correlated with degranulation (CD107a+) of 
KIR2DL1-SP NK cells in response to 221–C*08:02–ICP47 cells loaded with P10, P10-7E, P11, P11-7A, P2, P2-RA, P2-KA, P2-EE, or NP. CD107a expression was 
normalized to value obtained in response to NP for each donor. Spearman’s correlation, p = 0.0004, r = −0.95.
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at position 7 of the non-binding peptide P2-AA (IIDKSGAAV). 
The resulting P2-RA (IIDKSGRAV) peptide promoted binding of 
KIR2DL1 to HLA-C*08:02 (Figures 6A,B). This Arg-dependent 
gain-of-function was not reproduced with a Lys at position 7 
(P2-KA; IIDKSGKAV, in Figures  6A,B), suggesting specific 
recognition of Arg at position 7 by KIR2DL1 in the context of 
HLA-C*08:02.
To test whether cross-reactive KIR2DL1 binding to HLA-
C*08:02 resulted in functional inhibition of NK cytotoxicity, we 
generated 721.221 cells expressing HLA-C*08:02 (221–C*08:02; 
Additional File S8A,B in Supplementary Material), which were 
further transfected with the TAP inhibitor ICP47 (221–C*08:02–
ICP47). KIR2DL1-Fc bound 221–C*08:02–ICP47 cells that had 
been loaded with P10 (P10-IVDKSGRTL) (Additional File S8C 
in Supplementary Material). In assays using primary NK cells, 
KIR2DL1-SP NK cells degranulated in response to 221–C*08:02–
ICP47 cells not loaded with peptide (Figures 6C,D). Loading of 
221–C*08:02–ICP47 cells with peptide P10 (P10-IVDKSGRTL) 
resulted in inhibition of degranulation by KIR2DL1-SP cells, but 
not KIR3DL1-SP cells (Figure  6C). As expected, replacement 
of Arg at position 7 with Glu, P10-7E (IVDKSGETL) that 
impeded binding also eliminated inhibition (Figures  6B–D). 
We conclude that cross-reactive binding of KIR2DL1 to HLA-
C*08:02 loaded with peptide P10 (P10-IVDKSGRTL) resulted 
in functional inhibition of NK cell degranulation. While peptide 
P10 (P10-IVDKSGRTL) was compatible with canonical bind-
ing of KIR2DL1, KIR2DL2, and KIR2DL3 (Figure 2) and with 
cross-reactive KIR2DL1 binding to HLA-C*08:02 (Figure 6A), 
it formed a less effective ligand for cross-reactive binding of 
KIR2DL2 and KIR2DL3 to HLA-C*05:01 (Figure  3). Weak 
inhibition of degranulation by KIR2DL1-SP NK cells was 
detected with 221–C*08:02–ICP47 cells loaded with peptides 
that promoted weak KIR2DL1 binding, P11 (AGDDAPRAV) and 
P2-RA (IIDKSGRAV) (Figure 6D). Replacement of the Arg at 
position 7 of P2-RA (IIDKSGRAV) by Lys P2-KA (IIDKSGKAV) 
eliminated inhibition, as expected from the loss of binding 
(Figure 6B). Similar to KIR2DL3 with HLA-C*05:01, there was a 
strong inverse correlation between KIR2DL1-Fc binding to and 
degranulation of KIR2DL1-SP cells in response to 221–C*08:02–
ICP47 cells (Figure 6E). Degranulation of KIR3DL1-SP NK cells 
FigUre 7 | Kir2Dl2 and Kir2Dl3 are more peptide selective than 
Kir2Dl1 but less stringent about allotype preference. KIR2DL1, with 
strong specificity for C2 allotype, exhibits low peptide selectivity in binding 
C2. KIR2DL2 and KIR2DL3 cross-reactivity with C2 is associated with greater 
peptide selectivity. KIR2DL1 cross-reacted with C1 in the context of only two 
peptides. This hierarchy in peptide selectivity of killer cell Ig-like receptors 
(KIR)–HLA-C interactions is relevant to natural killer (NK) biology and 
understanding of disease associations. Peptide sequence-driven binding of 
KIR to HLA-C provides a potential mechanism for pathogen as well as 
self-peptide to modulate NK cell function through altering levels of KIR 
binding and KIR-mediated inhibition.
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was not inhibited by any of the peptides (Figure 6C; Additional 
File S8D in Supplementary Material). The ratio of KIR-Fc binding 
(as mean fluorescence intensity) to the extent of degranulation 
(as a fraction of each SP cell subset) was similar for KIR2DL1 
with HLA-C*08:02 and KIR2DL3 with HLA-C*05:01 (Additional 
File S8E in Supplementary Material). We conclude that the highly 
peptide-selective binding of KIR2DL1 to the group C1 allotype 
HLA-C*08:02 was competent to induce functional inhibition of 
KIR2DL1+ NK cells.
DiscUssiOn
Disease associations with different combinations of KIR and 
HLA-C genes have been interpreted through the “strength 
of inhibition” hypothesis, which posits that KIR2DL1 bind-
ing to a C2 allotype is a stronger interaction than KIR2DL3 
with C1 (3, 6–8, 10–15, 34) This hypothesis is based on the 
weaker binding of soluble KIR2DL3-Fc fusion protein to C1 
compared to KIR2DL1-Fc binding to C2, using HLA-C+ cells 
or HLA-C molecules attached to beads (27, 28, 35). Weaker 
interactions have been interpreted as potentially beneficial in 
viral infections such as HCV due to reduced inhibition of NK 
cells in individuals homozygous for C1 and for KIR2DL3 (9). 
Conversely, disorders of pregnancy in mothers carrying a C2/
C2 fetus and expressing KIR2DL1 on uterine NK cells have been 
interpreted as being due to stronger inhibition by KIR2DL1, 
resulting in decreased activation of specialized uterine NK cells 
that promote vascular remodeling to increase blood supply to 
the fetus (10, 11, 36, 37). However, the strength of inhibition 
hypothesis has to be reconciled with direct measurements of 
KIR binding to HLA-C in solution. Dissociation constants 
for KIR2DL1 with C2, and for KIR2DL2 and KIR2DL3 with 
C1, have been similar, ranging from 6.9 to 11.2 μM (25, 38, 
39). These measurements, obtained with recombinant HLA-C 
molecules that had been refolded with one peptide at a time, do 
not capture the complexity of KIR binding to cells expressing 
HLA-C molecules associated with a large repertoire of peptides. 
By examining how HLA-C-bound peptides regulate binding 
of KIR, we provide an explanation for the difference between 
solution binding measurements and strength of inhibition and 
demonstrate a hierarchy in the contribution of both HLA-C 
allotype and peptide sequence to KIR–HLA-C interactions 
(Figure 7). Our findings have direct implications for NK biol-
ogy and human disease associations.
We took advantage of the sequence identity of HLA-C*05:01 
(group C2) and HLA-C*08:02 (group C1) in all but for the two 
amino acids that define group C1 and C2 allotypes and specificity 
of KIR2DL1–C2 and KIR2DL2/3–C1 binding. This allowed us 
to specifically compare binding of KIR to C1 and C2 allotypes 
loaded with the same, single set of peptides. We eluted peptides 
from HLA-C*05:01 and showed that individual peptides could 
stabilize both HLA-C*05:01 and HLA-C*08:02 at the surface of 
TAP-deficient cells. Our hypothesis and conclusions do not rely 
on the assumption that HLA-C*08:02 has the same repertoire 
of endogenous peptides as those eluted from HLA-C*05:01. We 
show that KIR2DL2/3 binding to C1 is more selective for specific 
HLA-C–peptide complexes than KIR2DL1–C2, providing an 
explanation for the observation that KIR2DL3–C1 interactions 
appear to be weaker than KIR2DL1–C2.
KIR2DL1 bound to C2 allotype HLA-C*05:01 in the context 
of most peptides tested. In addition, we show that the peptide 
selectivity of KIR2DL2/3 binding was greater in the context of 
cross-reactive binding to the C2 allotype HLA-C*05:01. Cross-
reactive binding of KIR to non-canonical HLA-C allotypes has 
been described for KIR2DL2 and KIR2DL3 (26, 27). In the crystal 
structure of a KIR2DL2–HLA-C*03:04 complex the peptide side 
chains at positions 7 and 8 are both orientated upwards toward 
the KIR and are both making contacts (25), whereas peptide 
made no direct contribution to binding in the crystal structure 
of a KIR2DL1–HLA-C*04:01 complex (24). This is consistent 
with our data demonstrating a greater contribution of peptide 
sequence to canonical KIR2DL2/3 binding with C1 than to 
KIR2DL1 binding to C2.
The peptide sequence-dependent binding of KIR to HLA-C 
described here contrasts with the prevailing view that peptide 
selectivity of KIR binding to HLA-C is due mainly to peptide side 
chains at positions 7 and 8 of 9mers that interfere with binding 
through their bulk or charge (21, 25). Furthermore, KIR2DL2 
and KIR2DL3 binding is not governed simply by amino acids 
at positions 7 and 8. For example, replacing Arg-Ala at those 
positions in the peptide P2 with Ala-Ala did not affect KIR2DL2 
and KIR2DL3 canonical binding to C1 or cross-reactive binding 
to C2. The same Arg-Ala to Ala-Ala substitution in peptide P11 
eliminated binding of KIR2DL2 and KIR2DL3 to both C1 and 
C2 allotype. Finally, peptide P10 with Arg-Thr at positions 7 and 
8, which promoted strong KIR2DL2 and KIR2DL3 canonical 
binding, but weaker cross-reactive binding, gained strong cross-
reactive binding to HLA-C*05:01 when changed to Ala-Ala. Thus 
the contribution of positions 7 and 8 to binding of KIR2DL2 and 
KIR2DL3 is clearly tied to additional features of the peptide.
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KIR2DL1 has strong selectivity for C2 allotypes. Weak 
cross-reactive binding of KIR2DL1 was reported with group 
C1 HLA-Cw7 loaded with a single peptide but was not tested 
functionally (38, 39). We show here that two peptides loaded 
on the C1 allotype HLA-C*08:02 promoted KIR2DL1 binding, 
which resulted in functional inhibition of KIR2DL1+ NK cells. 
The crystal structure of a canonical KIR2DL1–HLA-C*04:01 
complex revealed a binding site made largely of shape com-
plementarity and of electrostatic forces between a positively 
charged HLA-C molecule and a negatively charged KIR (24). 
Lys80 of HLA-C*04:01 is accommodated by a specific pocket in 
KIR2DL1, in which Met44, Ser184, and Glu187 interact directly with 
HLA-C. The peptide made no direct contribution to binding, 
which may explain why KIR2DL1 binds to HLA-C*04:01 and, 
as shown here, to HLA-C*05:01 in the context of most peptides 
(21, 24). It is also consistent with the notion that KIR2DL1 and 
C2 allotypes have coevolved more recently than KIR2DL2/3 
with C1 allotypes as a more stringent KIR–HLA-C combina-
tion (29). Cross-reactive KIR2DL1 binding to HLA-C*08:02 
occurred only with peptides carrying Arg at position 7, suggest-
ing that an Arg at position 7 may compensate for the absence of 
the C2-defining Lys80.
Our data suggest a hierarchy in the contribution of both 
HLA-C allotype and peptide sequence in KIR binding (Figure 7). 
KIR2DL1, with strong specificity for C2 allotypes, binds C2 in 
the presence of most peptides. That peptide sequence contrib-
utes minimally to KIR2DL1 binding to C2 (21) is consistent 
with a lack of peptide contacts in the KIR2DL1–HLA-C*04:01 
crystal structure (24). Together with the greater propensity of 
KIR2DL2/3 to cross-react with C2 than KIR2DL1 with C1, the 
data suggest a more fundamental difference between KIR2DL2/3 
and KIR2DL1 binding to HLA-C, in which specificity for HLA-C 
allotype is inversely correlated with selectivity for peptides 
(Figure 7).
The use of HLA-C*05:01 and HLA-C*08:02 allotypes in our 
study has made it possible to examine and compare binding of 
KIR to a C2 and a C1 allotype in the context of the same peptides. 
There is a very large number of KIR combinations with HLA-C 
allotypes due to extensive polymorphism of KIR (29, 40–42) 
and of HLA-C. Canonical and cross-reactive binding of KIR to 
HLA-C and the contribution of peptide to the interaction may 
vary among different KIR–HLA-C combinations. KIR2DL2 and 
KIR2DL3 cross-reactive binding with C2 indeed varies among 
C2 allotypes (27).
The high polymorphism of the HLA-C peptide binding site 
is such that different HLA-C allotypes within group C1 or C2 
present very different peptide repertoires. Therefore, a specific 
and conserved recognition of an HLA-C–peptide complex can-
not be achieved by innate receptors such as KIR, which bind 
to a large number of HLA-C allotypes. Peptides that promote 
cross-reactive KIR binding should occur with a given prob-
ability for each HLA-C allotype and originate from endogenous 
host proteins as well as microbial pathogens. As an example, 
of five peptides from HIV Gag that were predicted to bind 
HLA-C*05:01, two promoted canonical binding of KIR2DL1, 
one of which also promoted cross-reactive binding of KIR2DL2 
and KIR2DL3. Similarly, a screen of peptides from two HCV 
proteins identified a 9mer sequence that promoted stronger 
binding of KIR2DL3 to HLA-C*03:04 than binding obtained 
with an endogenous peptide known to be associated with 
HLA-C*03:04 (43). These results illustrate the broader principle 
of immune subversion by intracellular pathogens capable of 
generating peptides that bind HLA-C and modulate inhibi-
tory KIR binding. Previous studies have reported HIV escape 
mutations that were associated with the presence of specific KIR 
genes, suggesting NK-mediated immune pressure on HIV (23). 
There was increased KIR binding to, and NK cell inhibition by, 
cells infected with viruses carrying the KIR-associated escape 
mutant. One of the HIV escape mutant peptides has been identi-
fied as a p24 Gag epitope, which promoted greater KIR2DL3 
canonical binding to HLA-C*03:04 than that of the original 
HIV Gag sequence (22). It is remarkable that the difference in 
binding to a single peptide can have an impact on KIR binding 
to cells that express a large repertoire of HLA-C–peptide com-
plexes. Analysis of peptide repertoires on virus-infected cells is 
needed to better understand viral evasion through inhibition 
of NK cells. As we have shown here, the specificity of KIR for 
HLA-C is such that a single amino acid change in the peptide 
can be sufficient to cause large differences in KIR binding and 
KIR-mediated inhibition, including cross-reactive KIR binding 
to a non-canonical HLA-C allotype.
A peptide that promotes strong KIR cross-reactivity could 
push NK cells that are normally unlicensed to a more licensed 
state through non-canonical KIR–HLA-C binding. This could 
occur in C1/C1 and C2/C2 homozygotes, as in either case SP 
KIR2DL1+ NK cells and SP KIR2DL2+ or KIR2DL3+ NK cells, 
respectively, lack a canonical HLA-C ligand. Immune pressure 
by NK cells may select for viral peptides that promote cross-
reactivity, given that unlicensed NK cells, which include cells 
with orphan inhibitory receptors, have been shown to provide 
stronger antiviral responses than licensed NK cells in MCMV-
infected and influenza virus-infected mice, and in EBV-infected 
humanized mice (44–47). According to this model, it would be 
harder for pathogens to evade SP KIR2DL1+ NK cells in C1/
C1 individuals than SP KIR2DL3+ NK cells in C2/C2, as the 
KIR2DL1–C1 cross-reactive combination is less prone to peptide 
sequence-dependent modulation. The new insights gained by our 
study suggest that interpretation of disease associations with KIR 
and C1 or C2 genes requires a better appreciation of the contribu-
tion of HLA-C-associated peptides to KIR binding and NK cell 
function.
MaTerials anD MeThODs
study Design
The goal of the study was to investigate the contribution of HLA-C 
bound peptides to canonical and cross-reactive KIR binding to 
C1 and C2 allotypes. In vitro experiments were carried out to test 
the level of soluble KIR-Fc binding to peptide-loaded HLA-C 
on TAP-deficient cells by flow cytometry. Experiments were 
repeated at least three times, and KIR-Fc binding was validated 
using functional experiments carried out with primary human 
NK cells from at least three healthy volunteers.
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hla-c Peptide sequencing
Human leukocyte antigen-C bound peptides were sequenced as 
described (48, 49). HLA-C was affinity purified from cell lysates 
of 1 ×  1010 221–C*05:01-His10 using a Ni2+ column followed 
by W6/32 column. NHS:N-hydroxysuccinimide-activated 
Sepharose 4 fast flow (Pharmacia Biotech) was incubated 
with W6/32 mAb (5  mg protein/ml Sepharose) overnight at 
room temperature. The column was blocked with 100  mM 
ethanolamine, pH 9.0, overnight before extensive washing with 
PBS. Filtered lysates of 221–C*05:01 cells were passed over a 
pre-column (IgG2a) followed by the W6/32 column. Columns 
were washed with 20 column volumes of lysis buffer, low salt 
buffer, high salt buffer, and no salt buffer. Lysis buffer was 
20 mM Tris-HCl pH 8.0 with 150 mM NaCl with 1% CHAPS, 
1 mM EDTA, 0.2% sodium azide, and protease inhibitors. Low 
salt buffer was 50 mM Tris-HCl with 250 mM NaCl (pH 8.0). 
High salt buffer was 50  mM Tris-HCl with 1  mM NaCl (pH 
8.0). No salt buffer was 50 mM Tris-HCl (pH 8.0). HLA-C was 
eluted from the W6/32 column with four-column volumes of 
0.2 M acetic acid. Peptides were separated by ultrafiltration to 
remove HLA-C heavy chain and β2M (3 kDa, Amicon Ultra-15; 
Millipore, USA). The filtrate was made up in 10% acetic acid 
and frozen. One milliliter was dried down in a speed vac and 
reconstituted at 1 × 107 cell equivalents/μl in 0.1% acetic acid. 
Approximately 2 × 107 cell equivalents were made up to 4 μl in 
0.1% acetic acid and spiked with 100  fmol internal standards 
angiotensin and vasoactive peptide. Sample was loaded onto 
an irregular C18 (5–20  μM diameter) capillary pre-column 
(360 μM outer diameter and 75 μM inner diameter) and washed 
with 0.1% acetic acid before connecting the pre-column to a C18 
analytical capillary column (360 μM outer diameter and 50 μM 
inner diameter) equipped with an electrospray emitter tip. 
Peptides were gradient eluted by increasing organic solvent from 
100% solvent A with 0% solvent B to 60% solvent B over 60 min 
(where solvent A is 0.1 M acetic acid in H2O and solvent B is 
70% acetonitrile and 0.1 M acetic acid). Ions were electrosprayed 
into a high-resolution mass spectrometer on elution (Thermo 
Orbitrap XL, USA). The five most abundant precursor masses 
present in MS1 were selectively fragmented in a linear ion trap 
by collision activated dissociation followed by electron transfer 
dissociation. On completion, the open mass spectrometry 
search algorithm was used to search the human RefSeq NCBI 
Reference Sequence Database (http://www.ncbi.nlm.nih.gov/
refseq/). Peptides were manually validated.
Peptide hla-c stabilization assays
Peptide stabilization of HLA-C was assessed by flow cytometry 
largely as described (19, 21, 33). A total of 1.25 × 105 cells were 
incubated overnight at 26°C with 100 μM of synthetic peptide, 
as indicated. The following day cells stained with PE-Cy5 
HLA-A, B, C, mAb (G46-2.6, BD) at 4°C. Peptides were syn-
thesized by GL Biochem (Shanghai Ltd., Shanghai, China) and 
Peptide 2.0 (USA).
Kir-Fc-Binding assay
Killer cell Ig-like receptors-Fc binding to cell lines and 
peptide-loaded cells was assessed by flow cytometry largely as 
described (19, 21). KIR2DL1*001-Fc, KIR2DL2*001-Fc and 
KIR2DL3*001-Fc (R&D, 1844-KR, 3015-KR, 2014-KR) were 
conjugated to protein-A Alexa Flour 647 (Invitrogen) by over-
night incubation at 9:1 (molar) at 4°C, then diluted to 3.6 μg/
ml in PBS + 2% fetal calf serum (FCS). A total of 1.25 × 105 cells 
were placed in 96 flat well plates, resuspended in 25 μl of KIR-Fc 
(3.6 μg/ml or as indicated) and incubated at 4°C for 1  h. For 
peptide loaded cells, KIR-Fc binding was assessed after overnight 
incubation at 26°C with 100 μM of synthetic peptide. KIR-Fc 
binding to 221 cells or protein A-Alexa Flour 647 alone were used 
to baseline values for KIR-Fc binding. Cells were washed with 
PBS and data acquired by flow cytometry.
nK cell Functional assays
Natural killer cell degranulation assays were carried out largely 
as described (19). For Figure 5 and Additional Files 3G,H and 
S7 in Supplementary Material, KIR A/A haplotype donor blood 
samples from healthy volunteers were recruited and collected 
under the Imperial College Healthcare NHS Trust Tissue Bank 
ethical approval (REC number 12/WA/0196). For Figure  6D 
and Additional File S8D in Supplementary Material, anonymous 
donors were recruited form the National Institutes of Health 
(NIH) blood bank. A total of 1 × 106 isolated PBMCs were incu-
bated overnight at 37°C with 10 ng/ml IL-15 (R&D) and mixed 
the following day at 5:1 with 221 cell lines or peptide-loaded target 
cells in presence of 1 μl BV421 anti-CD107a mAb for 2 h at 37°C 
(H4A3, BD 562623). PBMCs were stained with mAbs to identify 
KIR SP NK cells. NK cells were identified as CD56+ (NCAM16.2, 
BD 562780) and CD3− (SK7, BD 557832). KIR2DL3-SP NK cells 
were KIR2DL3+ (180701, R&D FAB2014F), KIR2DL1− (143211, 
R&D FAB1844P), KIR3DL1− (DX9, Miltenyi Biotec 130-092-
474) and NKG2A− (Z199, Beckman Coulter PNB10246). For 
Figure  6D and Additional File S8 in Supplementary Material, 
donors with unknown KIR genotypes were screened for expres-
sion for KIR2DL1 and KIR2DS1 with combinations of mAbs 
(143211 & EB6), as described (50). Flow cytometry panels were 
adjusted to allow isolation of KIR2DL1-SP NK cells if the donor 
carried KIR2DL1 and KIR2DS1. NK cell cytotoxicity assays were 
carried out with YTS NK cells mixed with 221 target cells at 
increasing effector target ratios, at 37°C for 2 h. For experiments 
with 221–HLA-C+ cell lines, the Europium release assay (Perkin 
Elmer, USA) was used as described (51). For assays using peptide 
loaded cells, propidium iodide incorporation assays were used as 
described (52).
cell lines
721.221 (221) cells and 221 cells expressing HLA-C*04:01 were 
used (provided by J. Gumperz and P. Parham, Stanford University, 
USA). The RMA-S cell line expressing HLA-C*08:02 is previously 
described (21). The 221 and RMA-S cell lines were cultured in 
RPMI or IMDM (Gibco) supplemented with 10% FCS. YTS 
cell lines were previously described and cultured in IMDM 
with 12.5% FCS (51). HLA-C*05:01 was expressed in 221 cells 
by retroviral transduction. Briefly, 293T cells stably expressing 
vesicular stomatitis virus (VSV) gag and pol genes were tran-
siently transfected by calcium phosphate with 6 μg each of VSV-
envelope glycoprotein and HLA-C*05:01 cDNAs. The medium 
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was changed at 24 h and harvested at 48 and 72 h for infection. 
On consecutive days, filtered virus-containing supernatant was 
incubated with untransfected 221 cells and 8 μg/ml polybrene. 
The plate was centrifuged at 1,000 × g, 32°C for 2 h. Two days 
after infection, cells were selected in 1 μg/ml puromycin. ICP47 
was expressed in 221 cell lines by electroporation as described 
(53, 54). Cell lines were cloned by limiting dilution after drug 
selection.
Flow cytometry
Killer cell Ig-like receptors-Fc binding, HLA-I stabilization, 
degranulation, and cytotoxicity assays were acquired on a FACS 
ARIA II (BD, UK). Instrument identification: BD FACSAria 
II SORP configuration number 39305 (NIHR BRC FACS and 
Confocal Imaging Facility, Hammersmith Campus, Imperial 
College London, UK). Fluidics configuration: 85  μm nozzle, 
45 psi, frequency of 45 kHz, and a window extension of 2. Optical 
configuration: 488 nm Laser Line: 780/50, 710/50, 670/14, 610/20, 
575/25, 488/10; 633 nm Laser Line: 780/60, 710/50, 670/14; and 
405 nm Laser Line: 610/20, 525/50, 450/40. Data were exported 
as FCS files and analyzed using FlowJo software (Treestar, ver-
sion 10). Compensation for multicolor experiments was set using 
single mAb-stained beads, and Cytometer Setup and Tracking 
beads were run daily.
human Donors
All studies were conducted according to the principles expressed 
in the Declaration of Helsinki. Healthy volunteers were recruited 
with informed consent with ethical approval either through the 
Imperial College Human Tissue Bank, London (REC number 12/
WA/0196) or from the NIH Department of Transfusion Medicine 
under an NIH Institutional Review Board-approved protocol 
with informed consent.
Plasmids
An HLA-C*05:01 cDNA (55) was supplied by Pierre Coulie, as 
plasmid pcDNA3.1–HLA-C*05:01 (de Duve Institute, Université 
Catholique de Louvain, UCL, Brussels, Belgium). Ten His 
residues followed by a stop codon were added to the C-terminus 
of HLA-C*05:01 by PCR of the HLA-C*05:01 cDNA. HLA-
C*05:01-10xHis was excised with BamHI and EcoRI and cloned 
into pBABE-puro-CMV+ by blunt-end ligation via the SalI site. 
pzLRS-ICP47-IRES-GFP (56) was supplied by Emmanuel Wiertz 
(Center of Infectious Diseases and Department of Medical 
Microbiology, Leiden University Medical Center, Leiden, The 
Netherlands). HLA-C*08:02 cDNA was generated by two sin-
gle base changes in codons 77 and 80 of HLA-C*05:01 cDNA 
(Figure  1A) by Quickchange PCR of HLA-C*05:01 using the 
primers.
Fwd: 5′-CAGACTGACCGAGTGAGCCTGCGGAACCT 
GCGCGGCTACTAC-3′ and Rev: 5′-GTAGTAGCCGCGCAGG 
TTCCGCAGGCTCACTCGGTCAGTCTG-3′.
statistical analysis
All statistical analysis was carried out using GraphPad PRISM 
(version 5.0). Multiple groups were compared by Kruskal–Wallis 
test with Dunn’s multiple comparisons test.
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aDDiTiOnal File s1 | sequence alignment of hla-c*05:01 and 
hla-c*08:02, generation of TaP-deficient cell line expressing 
hla-c*05:01 and correlation of hla-i stabilization. (a) Amino acid 
alignment of HLA-C*05:01 and HLA-C*08:02. Box indicates positions 77–80. (B) 
Expression of ICP47 (via IRES-GFP) and HLA-C in 221–C*05:01 cells transfected 
with pzLRS–ICP47-IRES-GFP. After drug selection, 221–C*05:01–ICP47 
cell line was cloned by limiting dilution. (c) Correlation of HLA-I stabilization. 
HLA-C*05:01 against HLA-C*08:02 (Spearman).
aDDiTiOnal File s2 | hla-c*05:01 eluted peptide sequences 
and relative abundance. The relative abundance: + = 0–29 copies/cell, 
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++ = 30–59 copies/cell, +++ = 60–100 copies/cell, and ++++ = >100  
copies/cell.
aDDiTiOnal File s3 | hla-c*05:01 is a functional ligand for Kir2Dl1, 
Kir2Dl2 and Kir2Dl3. (a) Expression of HLA-I and β2 microglobulin on 221, 
221–C*04:01 and 221–C*05:01 cells. (B,c) KIR2DL1-Fc, KIR2DL2-Fc, and 
KIR2DL3-Fc binding to 221, 221–C*04:01, and 221–C*05:01 cells as determined 
by flow cytometry. (c) Mean MFI and SEM are shown from three independent 
experiments. (D) Expression of KIR2DL1 and KIR2DL3 on YTS, YTS-2DL1, and 
YTS-2DL3 NK cells. (e) Specific lysis of 221, 221–C*04:01, and 221–C*05:01 
cells by YTS, YTS-2DL1, and YTS-2DL3 NK cells at different effector–target 
ratios (E:T). Mean and SEM of three independent experiments are shown. 
**p < 0.01 and ***p < 0.001 by Student’s t-test. (F) Flow cytometry gating 
strategy to identify KIR SP (KIR-SP) NK cells. CD56dim CD3− lymphocytes were 
identified from PBMCs. KIR2DL3-SP NK cells were identified as KIR3DL1− and 
NKG2A−, KIR2DL1− NK cells from A/A KIR haplotype donors. (g) Flow cytometry 
histograms showing degranulation (CD107a at the cell surface) of KIR3DL1 SP, 
KIR2DL1-SP, and KIR2DL3-SP NK cells in response to 221, 221–C*05:01, or 
no target cells. (h) Degranulation of KIR-SP NK cells in response to 221 and 
221–C*05:01 cells for N = 5 A/A KIR haplotype donors. Degranulation is shown 
relative to 221. ***p < 0.001 by Student’s t-test.
aDDiTiOnal File s4 | Kir2Dl2 and Kir2Dl3 binding to hla-c*08:02 is 
more peptide selective than Kir2Dl1 binding to hla-c*05:01. Data from 
Figure 2B normalized to HLA-I (KIF-Fc MFI/HLA-I MFI) for each peptide.
aDDiTiOnal File s5 | hla-c*05:01 hiV gag peptides modulate 
canonical and cross-reactive binding of Kir2Dl2 and Kir2Dl3 to hla-
c*05:01(c2). (a) HLA-C*05:01 HIV Gag 9mer peptide sequences.  
(B) Expression of HLA-I on 221–C*05:01–ICP47 cells loaded with no peptide 
(NP), P2 and HIV Gag peptides 50–58, 60–68, 305–313, 310–318, and 
427–435. Mean MFI and SEM of three independent experiments are shown.  
(c) Expression of HLA-I on RMA-S-C*08:02 cells loaded with NP, P2 and HIV 
Gag peptides 50–58, 60–68, 305–313, 310–318, and 427–435. Mean MFI and 
SEM of three independent experiments are shown. (D) KIR2DL1-Fc, KIR2DL2-Fc 
and KIR2DL3-Fc binding to 221–C*05:01–ICP47 cells loaded with NP, P2, or HIV 
Gag peptides, 50–58, 60–68, 305–313, 310–318, and 427–435. Mean MFI and 
SEM of three independent experiments are shown. (e) KIR2DL1-Fc, KIR2DL2-
Fc, and KIR2DL3-Fc binding to RMA-S-C*08:02 cells loaded with NP, P2, or HIV 
Gag peptides, 50–58, 60–68, 305–313, 310–318, and 427–435. Mean MFI and 
SEM of three independent experiments are shown.
aDDiTiOnal File s6 | stabilization of hla-i on TaP-deficient cells 
by peptides and cross-reactive binding of Kir2Dl2 to peptide-loaded 
hla-c*05:01 and Kir2Dl1 to peptide-loaded hla-c*08:02. (a) Sequences 
of peptides P2, P10, P11 and peptides with amino acid substitutions at positions 
7 and 8. (B) HLA-I expression on 221–C*05:01–ICP47 cells after overnight 
culture in the presence of HLA-C*05:01 peptides P2, P10, P11, and amino acid-
substituted peptides compared to cells with NP. Mean MFI and SEM of three 
independent experiments are shown. (c) HLA-I expression on RMA-S-C*08:02 
cells after overnight culture in the presence of HLA-C*05:01 peptides P2, P10, 
P11, and amino acid-substituted peptides compared to cells with NP. Mean MFI 
and SEM of three independent experiments are shown. (D) KIR2DL2-Fc (left) 
and KIR2DL1-Fc (right) binding to HLA-C*05:01 is correlated with binding to 
HLA-C*08:02 in the presence of the same peptides. All peptides with amino acid 
substitutions are shown.
aDDiTiOnal File s7 | Degranulation of Kir3Dl1-sP nK cells in 
response to peptide-loaded TaP-deficient hla-c*05:01 cells. KIR3DL1-SP 
NK cell CD107a expression (% positive) in response to 221–C*05:01–ICP47 cells 
loaded with NP, P2, P2-AA, P2-EE, P2-LA, P2-GG, P11, P11-7A, P10, P10-AA, 
and P10-7E. Individual donors are represented by different colors.
aDDiTiOnal File s8 | Kir-Fc binding and functional responses of Kir+ 
nK cells to 221-c*08:02 and 221-c*08:02-icP47 cells. (a) KIR2DL1-Fc, 
KIR2DL2-Fc, and KIR2DL3-Fc binding to 221, 221–C*08:02 and 221–C*15:01. 
(B) Specific lysis of 221 and 221–C*08:02 cells by YTS, YTS-2DL1, and YTS-
2DL3 NK cells. (c) KIR2DL1-Fc binding to 221–C*08:02–ICP47 cells loaded 
with NP or P10. (D) KIR3DL1-SP NK cell CD107a expression (% positive) in 
response to 221–C*08:02–ICP47 cells loaded with NP, P2, P2-AA, P2-EE, 
P2-LA, P2-GG, P11, P11-7A, P10, P10-AA, and P10-7E. Individual donors 
are represented by different colors. (e) Overlay of cross-reactive KIR-SP 
NK cell responses and cross-reactive KIR-Fc binding to HLA-C*05:01 and 
HLA-C*08:02.
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